EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Efficacy of curcumin plus piperine co‐supplementation in moderate‐to‐high hepatic steatosis: A double‐blind, randomized, placebo‐controlled clinical trial

Shima Sharifi, Mohammad Bagherniya iD, Ziba Khoram, Amrollah Ebrahimi Varzaneh, Stephen L Atkin, Tannaz Jamialahmadi iD, Amirhossein Sahebkar iD, Gholamreza Askari iD

Phytotherapy Research · 2023-06 · 37 (6) · 2217-2229

DOI: 10.1002/ptr.7764 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Phytotherapy Research, online erschienen am 17.02.2023. Verfasst von Shima Sharifi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nutrition and Food Security Research Center and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medica…. Hauptthemen laut MEDLINE: Curcumin, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Institute for Medical Research Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non‐alcoholic Fatty Liver Disease (NAFLD) is a global health problem that can progress to steatohepatitis and cirrhosis. The aim of this study was to determine the effect of curcumin + piperine on cardiometabolic risk factors, as well as hepatic steatosis and fibrosis in NAFLD patients with moderate‐to‐high hepatic steatosis. Patients diagnosed with moderate‐to‐high NAFLD by liver sonography were randomized to either curcumin + piperine (500 mg/day curcumin plus 5 mg/day piperine) for 12 weeks ( n = 30) or placebo groups ( n = 30). Liver fibroscan, anthropometric measurements, dietary intake, physical activity, blood pressure, lipid profile, high‐sensitivity C‐reactive protein, fasting blood glucose (FBG), and liver enzymes were assessed at baseline and after 12 weeks of follow‐up. Intention‐to‐treat analysis was undertaken. Curcumin + piperine decreased waist circumference ( p = 0.026), systolic blood pressure ( p = 0.001), total cholesterol ( p = 0.004), low‐density lipoprotein‐cholesterol ( p = 0.006), FBG ( p = 0.002), alanine transaminase ( p = 0.007) and aspartate transaminase ( p = 0.012) compared with placebo. However, fibroscan measurement did not differ between curcumin + piperine and placebo groups ( p > 0.05). Fibroscan measurement as a marker of NAFLD improvement did not differ after 12 weeks of curcumin + piperine; however, curcumin + piperine may be considered as an adjunct therapy to improve anthropometric measures, blood pressure, lipid profile, blood glucose, and liver function in NAFLD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CurcuminNon-alcoholic Fatty Liver DiseaseHumansBlood GlucoseDietary SupplementsDouble-Blind MethodLipidsCholesterolAlkaloidsPiperidinesBenzodioxolesPolyunsaturated Alkamides

Stichwörter der Autor:innen

controlled clinical trialcurcuminfatty livernon-alcoholic fatty liver diseasepiperine

Substanzen

CurcuminBlood GlucoseLipidsCholesterolpiperineAlkaloidsPiperidinesBenzodioxolesPolyunsaturated Alkamides

Autor:innen und Institutionen

  • Nutrition and Food Security Research Center and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Anesthesia and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • School of Postgraduate Studies and Research, RCSI Medical University of Bahrain, Busaiteen, Bahrain.
  • Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

ORCID-Profile: Mohammad Bagherniya, Tannaz Jamialahmadi, Amirhossein Sahebkar, Gholamreza Askari

Förderung

  • National Institute for Medical Research Development

Zitieren

APA

Sharifi, S., Bagherniya, M., Khoram, Z., Ebrahimi Varzaneh, A., Atkin, S. L., Jamialahmadi, T., Sahebkar, A., & Askari, G. (2023). Efficacy of curcumin plus piperine co‐supplementation in moderate‐to‐high hepatic steatosis: A double‐blind, randomized, placebo‐controlled clinical trial. Phytotherapy Research, 37(6), 2217-2229. https://doi.org/10.1002/ptr.7764

Vancouver

Sharifi S, Bagherniya M, Khoram Z, Ebrahimi Varzaneh A, Atkin SL, Jamialahmadi T, et al. Efficacy of curcumin plus piperine co‐supplementation in moderate‐to‐high hepatic steatosis: A double‐blind, randomized, placebo‐controlled clinical trial. Phytotherapy Research. 2023;37(6):2217-2229. doi:10.1002/ptr.7764

BibTeX
@article{Sharifi2023,
  author = {Sharifi, Shima and Bagherniya, Mohammad and Khoram, Ziba and Ebrahimi Varzaneh, Amrollah and Atkin, Stephen L and Jamialahmadi, Tannaz and Sahebkar, Amirhossein and Askari, Gholamreza},
  title = {Efficacy of curcumin plus piperine co‐supplementation in moderate‐to‐high hepatic steatosis: A double‐blind, randomized, placebo‐controlled clinical trial},
  journal = {Phytotherapy Research},
  year = {2023},
  volume = {37},
  number = {6},
  pages = {2217--2229},
  doi = {10.1002/ptr.7764}
}
Kostenlos starten →